Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Meredith M Regan, Sc.D.

Co-Author

This page shows the publications co-authored by Meredith Regan and David McDermott.
Connection Strength

3.422
  1. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res. 2021 12 15; 27(24):6687-6695.
    View in: PubMed
    Score: 0.969
  2. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019 12 10; 37(35):3350-3358.
    View in: PubMed
    Score: 0.834
  3. Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. Melanoma Res. 2022 02 01; 32(1):35-44.
    View in: PubMed
    Score: 0.246
  4. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. J Immunother Cancer. 2021 11; 9(11).
    View in: PubMed
    Score: 0.242
  5. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. Qual Life Res. 2019 Jan; 28(1):109-119.
    View in: PubMed
    Score: 0.194
  6. Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. Cancer J. 2017 Jan/Feb; 23(1):63-67.
    View in: PubMed
    Score: 0.173
  7. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8.
    View in: PubMed
    Score: 0.150
  8. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother. 2009 Feb-Mar; 32(2):181-5.
    View in: PubMed
    Score: 0.100
  9. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. Clin Genitourin Cancer. 2006 Sep; 5(2):114-9.
    View in: PubMed
    Score: 0.085
  10. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jan 01; 23(1):133-41.
    View in: PubMed
    Score: 0.075
  11. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6342S-6S.
    View in: PubMed
    Score: 0.074
  12. Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. Immunotherapy. 2020 01; 12(1):37-51.
    View in: PubMed
    Score: 0.054
  13. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Immunotherapy. 2019 03; 11(4):283-295.
    View in: PubMed
    Score: 0.050
  14. Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Immunotherapy. 2018 10; 10(14):1241-1252.
    View in: PubMed
    Score: 0.049
  15. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother. 2013 Nov-Dec; 36(9):490-5.
    View in: PubMed
    Score: 0.035
  16. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Sep; 106(6):772-8.
    View in: PubMed
    Score: 0.027
  17. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 01; 27(34):5794-9.
    View in: PubMed
    Score: 0.026
  18. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007 Sep; 5(6):379-85.
    View in: PubMed
    Score: 0.023
  19. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005 May 15; 11(10):3714-21.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.